Narrow-moat Daiichi Sankyo is ... early commercial success of Enhertu and good clinical data of Dato-DXd in previously treated lung cancer. Additionally, Daiichi Sankyo and its Enhertu commercial ...

Thank you for taking time out of your busy schedule to attend Daiichi Sankyo's Financial ... overexpressing non-small cell lung cancer patients treated with ENHERTU monotherapy.

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

“These three trials in either high PD-L1 expressing or EGFR mutated nonsquamous non-small cell lung ... each ADC. Daiichi Sankyo is responsible for the manufacturing and supply of ENHERTU ...

(Alliance News) - AstraZeneca PLC on Monday said that its antibody drug conjugate Enhertu won another approval ... by AstraZeneca and Tokyo-based Daiichi Sankyo Co Ltd. "Since our initial approval ...

Daiichi Sankyo ... ENHERTU has been conditionally approved by China's National Medical Products Administration (NMPA) as a single agent for adult patients with a specific type of non-small cell ...

On safety, there was a case of interstitial lung disease (ILD), a side effect that has been seen with other ADCs using Daiichi Sankyo's deruxtecan payload, like AstraZeneca's Enhertu (trastuzumab ...

NEW YORK – AstraZeneca and Daiichi Sankyo on Wednesday said ... patients across different lines and types of lung cancer," Mark Rutstein, global head of oncology clinical development at Daiichi Sankyo ...

(IN BRIEF) AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has received conditional approval in China for the treatment of patients with unresectable, locally advanced, or metastatic ...